RVLP - GAAP EPS of -$0.14 beats by $0.07 revenue of $8.45M misses by $0.07M

• press release ( NASDAQ: RVLP ): Q2 GAAP EPS of -$0.14 beats by $0.07 .
• Revenue of $8.45M (-26.6% Y/Y) misses by $0.07M .
• “Our recent financing and addition of Alisa Lask to our Board of Directors are strong signals of our growing belief in UPNEEQ ^® (oxymetazoline hydrochloride ophthalmic solution), 0.1%. Ms. Lask brings over 20 years of commercial experience in pharmaceuticals and medical aesthetics. Of note, she held senior leadership roles at Galderma and Allergan and currently holds the position of Chief Commercial Officer at RION, a development stage biotechnology company focused on regenerative medicine in medical and aesthetic applications. Our recent track record of growth and growing evidence of social proof have enabled us to attract outstanding talent from the industry and entertain a number of potentially exciting partnerships,” stated Brian Markison, Chief Executive Officer of RVL Pharmaceuticals plc.

For further details see: